Eng

Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®

PR Newswire (美通社)
更新於 14小時前 • 發布於 14小時前 • PR Newswire

MELBOURNE, Australia, Oct. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix's commercial PSMA-PET[1] product, Illuccix® (68Ga-PSMA-11).

Subtle Medical's SubtlePET™ is a U.S. Food and Drug Administration (FDA) cleared AI-driven solution to enhance the efficiency and effectiveness of imaging procedures. The proprietary deep-learning algorithm allows for faster PET scanning – up to 75% time savings without compromising image quality. The technology represents a significant advancement in the field, offering numerous benefits to patients, physicians, and medical facilities.

廣告(請繼續閱讀本文)

SubtlePET's ability to expedite the imaging process reduces patient wait times and increases comfort, with the patient required to remain motionless under the camera for a shorter period of time, contributing to an overall more positive healthcare experience. Additionally, a shorter scan time for Illuccix will allow healthcare providers to further optimise workflows and resource utilisation. Most importantly for facilities, SubtlePET seamlessly integrates into existing imaging center workflows, empowering healthcare providers to achieve faster PET imaging on any scanner, regardless of manufacturer or model. The technology can also extend scanner life through improved performance.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, "Through this partnership, we are excited to incorporate an innovative AI product into the Illuccix value proposition for our customers and the patients they serve. We believe that the combination of Illuccix and SubtlePET will further strengthen Telix's AI toolkit and also Illuccix's reputation as the best-in-class PSMA-PET imaging agent for accuracy, reliability, quality, and operational excellence in the U.S. As Telix looks to our future with a multi-product portfolio, we look forward to growing our partnership with Subtle Medical to advance patient care and more efficient PET workflows across the disease spectrum."

Josh Gurewitz, Chief Commercial Officer, Subtle Medical, commented, "We are pleased to commercially partner with Telix, a global leader in theranostics. This agreement represents a significant milestone for both companies, as we join forces to empower medical professionals and improve outcomes for patients with Subtle Medical's platform and innovative AI product for PET imaging, starting with prostate cancer."

廣告(請繼續閱讀本文)

The partnership with Telix, which covers North America and the European Union (EU, excluding France and French speaking Belgium), launches in the United States (U.S.) with Illuccix, with the aim to expand to other Telix PET-tracers, subject to regulatory approval.

To sign up for more information on Illuccix and SubtlePET visit

About Subtle Medical, Inc.

廣告(請繼續閱讀本文)

Subtle Medical is a leading innovator in medical imaging software, utilising advanced AI technologies to enhance the efficiency and effectiveness of imaging procedures. The company's solutions, SubtlePET™ and SubtleMR™, leverage proprietary algorithms to improve scan times and image quality, aiming to improve patient outcomes and the diagnostic process. SubtlePET has received 510(k) clearance from the FDA and is Conformité Européenne (CE) marked in the EU for use with multiple PET tracers. Subtle Medical is committed to transforming medical imaging through its cutting-edge solutions, making it faster, safer, and more accessible to patients worldwide. For more information, please visit or email

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Telix's lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. FDA[2], by the Australian Therapeutic Goods Administration (TGA)[3], and by Health Canada[4].

Visit for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email:

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX) or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

[1] Imaging of prostate-specific membrane antigen with positron emission tomography.

[2] Telix ASX disclosure 20 December 2021.

[3] Telix ASX disclosure 2 November 2021.

[4] Telix ASX disclosure 14 October 2022.

查看原始文章

更多 Eng 相關文章

GLOBALink | China's eVTOL enterprise to showcase latest product at CIIE
XINHUA
Xinhua News | 31 killed, 27 injured in Israeli airstrikes on Lebanon
XINHUA
MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024
PR Newswire (美通社)
TIER IV's AI Pilot system certified for Level 4 autonomous bus service in Nagano Prefecture
PR Newswire (美通社)
The 2024 Asia Green and Low-Carbon Development Roundtable was held
PR Newswire (美通社)
Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration
PR Newswire (美通社)
AIKO Showcases its High-Efficiency N-type ABC Modules at All Energy Australia
PR Newswire (美通社)
Yeouido Hangang Park, Painted with the Colors of Global Culture: '2024 Asia Song Festival X Culture Bridge Festa' Concludes Successfully
PR Newswire (美通社)
China's sports industry unleashes potential in the past decade
XINHUA
GLOBALink | China launches Shenzhou-19 crewed spaceship
XINHUA
China's manufacturing sector resumes expansion in October
XINHUA
Vlog| Who's the best tour guide? Huangling's top autumn experiences face off
XINHUA
Xinhua News | China activates emergency response as super typhoon nears
XINHUA
Interview: CIIE a key platform for deepening Sino-Swiss economic cooperation, says former Swiss ambassador to China
XINHUA
China's non-manufacturing PMI at 50.2 in October
XINHUA
Regal Hotels Pioneers Green Meetings Elevating Sustainable Practices for MICE Events in Hong Kong
PR Newswire (美通社)
Profile: Wang Haoze -- female rocket engineer launched into space
XINHUA
Eat Like a Shogun in Saitama-Kawaguchi -November 2024 to January 2025
PR Newswire (美通社)
Asia Album: Indonesia's int'l fashion festival 2024
XINHUA
Hang Seng Investment Collaborates with SAB Invest | Launch of SAB Invest Hang Seng Hong Kong ETF on the Saudi Exchange
PR Newswire (美通社)
Chinese table tennis great Ma Long wins ANOC Outstanding Sporting Career Award
XINHUA
China launches Shenzhou-19 crewed spaceship
XINHUA
Chinese FM meets Russian deputy FM in Beijing
XINHUA
MGM China Reports 2024 Nine-Month Results
PR Newswire (美通社)
China-donated aid distributed to needy families in W. Afghanistan
XINHUA
Jolicare's Journey: From Steroid Scandal to Leading Herbal Skincare Brand
PR Newswire (美通社)
EcoChina | Milu reserve saw 825 newborns of milu deer in E China's Jiangsu
XINHUA
Peking University HSBC Business School Marks 20th Anniversary
PR Newswire (美通社)
Xinhua News | Typhoon Trami leaves 7 dead, 1 missing in China's Hainan
XINHUA
JACOB & CO. Boutique Debuts in Macao: A Perfect Fusion of Art and Luxury
PR Newswire (美通社)